149 related articles for article (PubMed ID: 35420780)
21. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
[TBL] [Abstract][Full Text] [Related]
22. IGF-1/IGF-1R/FAK/YAP Transduction Signaling Prompts Growth Effects in Triple-Negative Breast Cancer (TNBC) Cells.
Rigiracciolo DC; Nohata N; Lappano R; Cirillo F; Talia M; Scordamaglia D; Gutkind JS; Maggiolini M
Cells; 2020 Apr; 9(4):. PubMed ID: 32325700
[TBL] [Abstract][Full Text] [Related]
23. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity.
Cao D; Zhu GY; Lu Y; Yang A; Chen D; Huang HJ; Peng SX; Chen LW; Li YW
Biomed Pharmacother; 2020 Sep; 129():110462. PubMed ID: 32768952
[TBL] [Abstract][Full Text] [Related]
24. New 3-alkylpyridine marine alkaloid analogues as promising antitumor agents against the CD44
de Lima AB; Barbosa CS; Gonçalves AMMN; Santos FVD; Viana GHR; Varotti FP; Silva LM
Chem Biol Drug Des; 2017 Jul; 90(1):5-11. PubMed ID: 27995747
[TBL] [Abstract][Full Text] [Related]
25. Autophagy promotes triple negative breast cancer metastasis via YAP nuclear localization.
Chen W; Bai Y; Patel C; Geng F
Biochem Biophys Res Commun; 2019 Dec; 520(2):263-268. PubMed ID: 31590917
[TBL] [Abstract][Full Text] [Related]
26. PGM5P3-AS1 regulates MAP1LC3C to promote cell ferroptosis and thus inhibiting the malignant progression of triple-negative breast cancer.
Qi L; Sun B; Yang B; Lu S
Breast Cancer Res Treat; 2022 Jun; 193(2):305-318. PubMed ID: 35325342
[TBL] [Abstract][Full Text] [Related]
27. RBCK1 is an endogenous inhibitor for triple negative breast cancer via hippo/YAP axis.
Li Z; Su P; Ding Y; Gao H; Yang H; Li X; Yang X; Xia Y; Zhang C; Fu M; Wang D; Zhang Y; Zhuo S; Zhu J; Zhuang T
Cell Commun Signal; 2022 Oct; 20(1):164. PubMed ID: 36280829
[TBL] [Abstract][Full Text] [Related]
28. Ultrasound-Targeted Microbubble Disruption with Key Nanodroplets for Effective Ferroptosis in Triple-Negative Breast Cancer Using Animal Model.
Liu R; Shi D; Guo L; Xiao S; Shang M; Sun X; Meng D; Zhao Y; Wang X; Li J
Int J Nanomedicine; 2023; 18():2037-2052. PubMed ID: 37155504
[TBL] [Abstract][Full Text] [Related]
29. Tiliroside induces ferroptosis to repress the development of triple-negative breast cancer cells.
Hu C; Zhao JF; Wang YM; Wu XL; Ye L
Tissue Cell; 2023 Aug; 83():102116. PubMed ID: 37301139
[TBL] [Abstract][Full Text] [Related]
30. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.
Barkal AA; Brewer RE; Markovic M; Kowarsky M; Barkal SA; Zaro BW; Krishnan V; Hatakeyama J; Dorigo O; Barkal LJ; Weissman IL
Nature; 2019 Aug; 572(7769):392-396. PubMed ID: 31367043
[TBL] [Abstract][Full Text] [Related]
31. Glutathione depletion and dihydroorotate dehydrogenase inhibition actuated ferroptosis-augment to surmount triple-negative breast cancer.
Zhou TJ; Zhang MM; Liu DM; Huang LL; Yu HQ; Wang Y; Xing L; Jiang HL
Biomaterials; 2024 Mar; 305():122447. PubMed ID: 38154441
[TBL] [Abstract][Full Text] [Related]
32. Decreased expression of autophagy protein LC3 and stemness (CD44+/CD24-/low) indicate poor prognosis in triple-negative breast cancer.
Chang SJ; Ou-Yang F; Tu HP; Lin CH; Huang SH; Kostoro J; Hou MF; Chai CY; Kwan AL
Hum Pathol; 2016 Feb; 48():48-55. PubMed ID: 26772398
[TBL] [Abstract][Full Text] [Related]
33. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
34. Nucleophosmin/B23 promotes endometrial cancer cell escape from macrophage phagocytosis by increasing CD24 expression.
Lin CY; Tsai CL; Chao A; Lee LY; Chen WC; Tang YH; Chao AS; Lai CH
J Mol Med (Berl); 2021 Aug; 99(8):1125-1137. PubMed ID: 33954835
[TBL] [Abstract][Full Text] [Related]
35. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy.
Yang F; Xiao Y; Ding JH; Jin X; Ma D; Li DQ; Shi JX; Huang W; Wang YP; Jiang YZ; Shao ZM
Cell Metab; 2023 Jan; 35(1):84-100.e8. PubMed ID: 36257316
[TBL] [Abstract][Full Text] [Related]
36. Ferroptosis: the emerging player in remodeling triple-negative breast cancer.
Li J; He D; Li S; Xiao J; Zhu Z
Front Immunol; 2023; 14():1284057. PubMed ID: 37928550
[TBL] [Abstract][Full Text] [Related]
37. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
[TBL] [Abstract][Full Text] [Related]
38. GPER/Hippo-YAP signal is involved in Bisphenol S induced migration of triple negative breast cancer (TNBC) cells.
Deng Q; Jiang G; Wu Y; Li J; Liang W; Chen L; Su Q; Li W; Du J; Wong CKC; Chen Z; Wang H
J Hazard Mater; 2018 Aug; 355():1-9. PubMed ID: 29758456
[TBL] [Abstract][Full Text] [Related]
39. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.
Hu K; Law JH; Fotovati A; Dunn SE
Breast Cancer Res; 2012 Feb; 14(1):R22. PubMed ID: 22309939
[TBL] [Abstract][Full Text] [Related]
40. SASH1 suppresses triple-negative breast cancer cell invasion through YAP-ARHGAP42-actin axis.
Jiang K; Liu P; Xu H; Liang D; Fang K; Du S; Cheng W; Ye L; Liu T; Zhang X; Gong P; Shao S; Wang Y; Meng S
Oncogene; 2020 Jul; 39(27):5015-5030. PubMed ID: 32523092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
